statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial...

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., April 10, 2024...

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Thursday. Other...

Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Rating Lowered by StockNews.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) has been given a consensus rating of "Moderate Buy" by the four research firms that are covering the firm, MarketBeat Ratings reports. Two...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $5.05 Average Price Target from Analysts

Rigel Announces Publication of Data on REZLIDHIA (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma Rigel Announces Publication of Data on REZLIDHIA (Olutasidenib...

Rigel Announces Publication of Data on REZLIDHIA (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Thursday.
Several other...

Rigel Pharmaceuticals (NASDAQ:RIGL) Lowered to "Hold" at StockNews.com

In trading on Monday, biotechnology shares were relative laggards, down on the day by about 1.9%. Helping drag down the group were shares of Disc Medicine, down about 56.3% and shares of Rigel...

Video: Monday Sector Laggards: Biotechnology, Water Utilities

Investors eyeing a purchase of Rigel Pharmaceuticals Inc (RIGL) stock, but cautious about paying the going market price of 1.44/share, might benefit from considering selling puts among the...

Commit To Buy Rigel Pharmaceuticals At $1, Earn 20.1% Annualized Using Options

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL  Free Report)  Research analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Rigel Pharmaceuticals in a report...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Expected to Earn FY2024 Earnings of ($0.11) Per Share

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire...

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Volume	791,587.00
52-Wk High	$1.96
52-Wk Low	$0.712

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.03	--	--	N/A
Q4'23	-$0.02	$0.00	100.00%	BEAT
Q3'23	-$0.07	-$0.03	57.74%	BEAT
Q2'23	-$0.08	-$0.04	48.74%	BEAT
Q1'23	-$0.10	-$0.08	16.48%	BEAT

RIGL Rigel Pharmaceuticals

About

Feed

News

Sentiment

Earnings

Fundamentals